1. 1) 青木延雄, 長谷川淳 : DIC診断基準の「診断のための補助的検査成績, 所見」の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度研究報告書. 37-41, 1988.
2. 2) Wada H, Wakita Y, Nakase T, et al. the Mie DIC study group : Outcome of disseminated intravascular coagulation in relation to the score when treatment begun. Thromb Haemost 74 : 848-852, 1995.
3. Guidelines for program content for fellowship training in critical care medicine
4. 4) Bernard G, Vincent JL, Laterre PF, et al for the recombinant human activat edprotein C worldwide evaluation in severe sepsis (PROWESS) study group : Efficacy and safety of recombinant human acitvated protein C for severe sepsis. N Engl J Med 344 : 699-709, 2001.
5. 5) FDA briefing document : Anti-infective advisory com-mittee Drotrecogin alfa (activated) [recombinant humanactivated protein C (rhAPC)] XigrisTM BLA #125029/0 September 12, 2001. p18